Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib.
Ilario Giovanni RapposelliToshifumi TadaShigeo ShimoseValentina BurgioTakashi KumadaHideki IwamotoAtsushi HiraokaTakashi NiizekiMasanori AtsukawaHironori KogaMasashi HirookaTakuji TorimuraMassimo IavaroneRaffaella TortoraClaudia CampaniSara LonardiEmiliano TamburiniPiscaglia FabioGianluca MasiGiuseppe CabibboFrancesco Giuseppe FoschiMarianna SillettaKunihiko TsujiToru IshikawaKoichi TakaguchiKazuya KariyamaEi ItobayashiKazuto TajiriNoritomo ShimadaHiroshi ShibataHironori OchiSatoshi YasudaHidenori ToyodaShinya FukunishiHideko OhamaKazuhito KawataJoji TaniShinichiro NakamuraKazuhiro NousoAkemi TsutsuiTakuya NaganoTakaaki TanakaNorio ItokawaTomomi OkuboTaeang AraiMichitaka ImaiKouji JokoYohei KoizumiYoichi HiasaMargherita RiminiFrancesca RattiLuca AldrighettiStefano CascinuAndrea Casadei-GardiniPublished in: Liver international : official journal of the International Association for the Study of the Liver (2021)
Our main findings are that the occurrence of arterial hypertension G ≥ 2 is a predictor of longer survival, whereas decreased appetite G ≥ 2 predicts for a poor prognosis. A careful management of AEs under lenvatinib treatment for HCC is required, to improve patients' quality of life, minimize the need for treatment discontinuation and achieve optimal outcome.